Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein

Melissa Burton, Hiroyuki Nakai, Peter Colosi, Janet Cunningham, Rachel Mitchell, Linda Couto

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

We are interested in using recombinant adeno-associated viral vectors in the treatment of hemophilia A. Because of the size constraints of recombinant adeno-associated viral vectors, we delivered the heavy and light chains of the human factor 8 (hFVIII) cDNA independently by using two separate vectors. Recombinant AAV vectors were constructed that utilized the human elongation factor 1α promoter, a human growth factor polyadenylation signal, and the cDNA sequences encoding either the heavy or light chain of hFVIII. Portal vein injections of each vector alone, a combination of both vectors, or a hFIX control vector were performed in C57BL/6 mice. An ELISA specific for the light chain of hFVIII demonstrated very high levels (2-10 μg/ml) of protein expression in animals injected with the light chain vector alone or with both vectors. We utilized a chromogenic assay in combination with an antibody specific to hFVIII to determine the amount of biologically active hFVIII in mouse plasma. In animals injected with both the heavy and light chain vectors, greater than physiological levels (200-400 ng/ml) of biologically active hFVIII were produced. This suggests that coexpression of the heavy and light chains of hFVIII may be a feasible approach for treatment of hemophilia A.

Original languageEnglish (US)
Pages (from-to)12725-12730
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume96
Issue number22
DOIs
StatePublished - Oct 26 1999
Externally publishedYes

Fingerprint

Factor VIII
Light
Proteins
Hemophilia A
Complementary DNA
Peptide Elongation Factor 1
Polyadenylation
Protein Sorting Signals
Portal Vein
Inbred C57BL Mouse
Intercellular Signaling Peptides and Proteins
Enzyme-Linked Immunosorbent Assay
Injections
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. / Burton, Melissa; Nakai, Hiroyuki; Colosi, Peter; Cunningham, Janet; Mitchell, Rachel; Couto, Linda.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 22, 26.10.1999, p. 12725-12730.

Research output: Contribution to journalArticle

@article{91987c88f9d64179a6152e1415be456f,
title = "Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein",
abstract = "We are interested in using recombinant adeno-associated viral vectors in the treatment of hemophilia A. Because of the size constraints of recombinant adeno-associated viral vectors, we delivered the heavy and light chains of the human factor 8 (hFVIII) cDNA independently by using two separate vectors. Recombinant AAV vectors were constructed that utilized the human elongation factor 1α promoter, a human growth factor polyadenylation signal, and the cDNA sequences encoding either the heavy or light chain of hFVIII. Portal vein injections of each vector alone, a combination of both vectors, or a hFIX control vector were performed in C57BL/6 mice. An ELISA specific for the light chain of hFVIII demonstrated very high levels (2-10 μg/ml) of protein expression in animals injected with the light chain vector alone or with both vectors. We utilized a chromogenic assay in combination with an antibody specific to hFVIII to determine the amount of biologically active hFVIII in mouse plasma. In animals injected with both the heavy and light chain vectors, greater than physiological levels (200-400 ng/ml) of biologically active hFVIII were produced. This suggests that coexpression of the heavy and light chains of hFVIII may be a feasible approach for treatment of hemophilia A.",
author = "Melissa Burton and Hiroyuki Nakai and Peter Colosi and Janet Cunningham and Rachel Mitchell and Linda Couto",
year = "1999",
month = "10",
day = "26",
doi = "10.1073/pnas.96.22.12725",
language = "English (US)",
volume = "96",
pages = "12725--12730",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "22",

}

TY - JOUR

T1 - Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein

AU - Burton, Melissa

AU - Nakai, Hiroyuki

AU - Colosi, Peter

AU - Cunningham, Janet

AU - Mitchell, Rachel

AU - Couto, Linda

PY - 1999/10/26

Y1 - 1999/10/26

N2 - We are interested in using recombinant adeno-associated viral vectors in the treatment of hemophilia A. Because of the size constraints of recombinant adeno-associated viral vectors, we delivered the heavy and light chains of the human factor 8 (hFVIII) cDNA independently by using two separate vectors. Recombinant AAV vectors were constructed that utilized the human elongation factor 1α promoter, a human growth factor polyadenylation signal, and the cDNA sequences encoding either the heavy or light chain of hFVIII. Portal vein injections of each vector alone, a combination of both vectors, or a hFIX control vector were performed in C57BL/6 mice. An ELISA specific for the light chain of hFVIII demonstrated very high levels (2-10 μg/ml) of protein expression in animals injected with the light chain vector alone or with both vectors. We utilized a chromogenic assay in combination with an antibody specific to hFVIII to determine the amount of biologically active hFVIII in mouse plasma. In animals injected with both the heavy and light chain vectors, greater than physiological levels (200-400 ng/ml) of biologically active hFVIII were produced. This suggests that coexpression of the heavy and light chains of hFVIII may be a feasible approach for treatment of hemophilia A.

AB - We are interested in using recombinant adeno-associated viral vectors in the treatment of hemophilia A. Because of the size constraints of recombinant adeno-associated viral vectors, we delivered the heavy and light chains of the human factor 8 (hFVIII) cDNA independently by using two separate vectors. Recombinant AAV vectors were constructed that utilized the human elongation factor 1α promoter, a human growth factor polyadenylation signal, and the cDNA sequences encoding either the heavy or light chain of hFVIII. Portal vein injections of each vector alone, a combination of both vectors, or a hFIX control vector were performed in C57BL/6 mice. An ELISA specific for the light chain of hFVIII demonstrated very high levels (2-10 μg/ml) of protein expression in animals injected with the light chain vector alone or with both vectors. We utilized a chromogenic assay in combination with an antibody specific to hFVIII to determine the amount of biologically active hFVIII in mouse plasma. In animals injected with both the heavy and light chain vectors, greater than physiological levels (200-400 ng/ml) of biologically active hFVIII were produced. This suggests that coexpression of the heavy and light chains of hFVIII may be a feasible approach for treatment of hemophilia A.

UR - http://www.scopus.com/inward/record.url?scp=0033607305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033607305&partnerID=8YFLogxK

U2 - 10.1073/pnas.96.22.12725

DO - 10.1073/pnas.96.22.12725

M3 - Article

C2 - 10535990

AN - SCOPUS:0033607305

VL - 96

SP - 12725

EP - 12730

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 22

ER -